Results 91 to 100 of about 14,668 (165)

DARATUMUMAB: REVISÃO DA ATUAÇÃO E INTERFERÊNCIA NOS TESTES PRÉ- TRANSFUSIONAIS EM PACIENTES COM DIAGNOSTICO DE MIELOMA MÚLTIPLO

open access: yesHematology, Transfusion and Cell Therapy
Objetivo: Discutir a interferência da medicação Daratumumab nos testes pré-transfusionais em amostras de pacientes diagnosticados com Mieloma Múltiplo que necessitam de transfusões sanguíneas.
GN Leôncio
doaj   +1 more source

An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers

open access: yesAdvanced Science
First‐line treatment of multiple myeloma, a prevalent blood cancer lacking a cure, using anti‐CD38 daratumumab antibody and lenalidomide is often inadequate due to relapse and severe side effects.
Yueh‐Hsiang Yu   +11 more
doaj   +1 more source

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab

open access: yes, 2017
Purpose: Daratumumab treatment results in a marked reduction of CD38 expression on multiple myeloma cells. The aim of this study was to investigate the clinical implications and the underlying mechanisms of daratumumab-mediated CD38 reduction ...
Sasser, A Kate   +35 more
core   +1 more source

Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo–Expanded Autologous NK Cells

open access: yes, 2018
Purpose: Daratumumab and its use in combination with other agents is becoming a new standard of care for the treatment of multiple myeloma. We mechanistically studied how daratumumab acts on natural killer (NK) cells.
Don M. Benson   +6 more
core   +1 more source

Pretransfusion Testing and Daratumumab: Assessing Interference Risks and Developing Solutions

open access: yesGlobal Journal of Transfusion Medicine
Daratumumab is a monoclonal antibody; anti-CD38 is used for the treatment of multiple myeloma and other hematological disorders. Daratumumab, binds to CD 38 on red blood cells (RBCs), interfering with pretransfusion testing. This interference can lead to
Saroj Rajput   +3 more
doaj   +1 more source

Rapid identification of daratumumab interference with M-protein detection using MALDI-TOF mass spectrometry: a case study involving renal light chain amyloidosis

open access: yesPractical Laboratory Medicine
Therapeutic monoclonal antibodies (t-mAbs), such as daratumumab (anti-CD38), are increasingly used in plasma cell disorders including systemic AL amyloidosis.
Hou-Long Luo, Anping Xu, Ling Ji
doaj   +1 more source

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

open access: yes, 2011
CD38, a type II transmembrane glycoprotein highly expressed in hematological malignancies including multiple myeloma (MM), represents a promising target for mAb-based immunotherapy.
Jan G. J. van de Winkel   +31 more
core   +1 more source

P183 | DELAYED DARATUMUMAB ADDITION TO LENALIDOMIDE-DEXAMETHASONE IN OLDER MULTIPLE MYELOMA PATIENTS: INSIGHTS FROM REAL-WORLD DATA

open access: yesHaematologica
Introduction In patients (pts) with multiple myeloma (MM), the combination of daratumumab, lenalidomide, and dexamethasone (Dara-Rd) is a standard of care, approved both for frontline treatment of non-transplant eligible (NTE) pts and in the relapsed ...
L. Cani   +15 more
doaj  

Freeze-dried kit formulation and physicochemical assessment of a daratumumab-based radiopharmaceutical [PDF]

open access: yes
Daratumumab is a fully human anti-CD38 monoclonal antibody with strong potential as a targeting vector for therapeutic radionuclides. This study aimed to develop a freeze-dried daratumumab immunoconjugate kit by selecting a suitable chelator (DOTA ...
Davalieva, Katarina   +10 more
core   +1 more source

Daratumumab and Romiplostim Combined Therapy for a Long-Standing Refractory Primary Immune Thrombocytopenia – Case Report [PDF]

open access: yes
Ibrahim Zoubi,1 Amir Warwar,1,2 Shoshan Perek,1 Meir Preis1,2 1Institute of Hematology, Lady Davis Carmel Medical Center, Haifa, Israel; 2Bruce and Ruth Rappaport Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, IsraelCorrespondence:
Preis M, Warwar A, Perek S, Zoubi I
core  

Home - About - Disclaimer - Privacy